GlassScriptPhysician profile
Ruben L Velez
NPI 1053382879
$3,321.23
in general payments reported to CMS, 2019-2025
29 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $15.02 · 2021: $11.78 · 2022: $591 · 2023: $608 · 2024: $1,049 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Education: $13.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.05 |
| Education | $13.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $628.67 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $548.24 | 2019-2025 | Nxstage System One, Velphoro, Velphoro |
| Amgen INC. | $357.87 | 2024-2025 | Krystexxa, Tavneos, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $252.13 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $172.90 | 2023-2025 | Lupkynis |
| Cormedix INC. | $163.79 | 2024-2025 | Defencath, Defencath |
| Vifor Pharma, INC. | $138.36 | 2022-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $119.99 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $119.12 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.36 | 2022-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $82.94 | 2023-2025 | Acthar |
| Travere Therapeutics, INC. | $75.00 | 2022-2025 | Filspari |
| Glaxosmithkline, LLC. | $71.78 | 2022-2024 | Benlysta |
| Ardelyx, INC. | $51.63 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $50.64 | 2025 | Prevymis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $50.24 | 2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $40.20 | 2023-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $38.38 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $36.61 | 2023-2025 | |
| Recor Medical INC | $34.41 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Baxter Healthcare | $28.58 | 2024 | Renal - Acute |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.54 | 2024 | |
| Novo Nordisk INC | $24.56 | 2025 | Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $23.03 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.89 | 2022 | |
| Nxstage Medical, INC. | $21.31 | 2022 | |
| Shield Therapeutics INC | $15.62 | 2025 | |
| Akebia Therapeutics INC | $15.02 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.42 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.